Details of the Drug

General Information of Drug (ID: DMNKLZM)

Drug Name

TgAAG76

Synonyms

RAAV 2/2.hRPE65p.hRPE65; AAV RPE65 gene therapy (RPE65-mediated blindness), Targeted Genetics/University of London/Moorfields

Indication

Disease Entry	ICD 11	Status	REF
Blindness	9D90	Phase 1/2	[1]
------------------------------------------------------------------------------------

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Retinal pigment epithelium protein (RPE65)	TTBOH16	RPE65_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT00643747) Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis. U.S. National Institutes of Health.
2	tgAAG76, an adeno-associated virus delivered gene therapy for the potential treatment of vision loss caused by RPE65 gene abnormalities. Curr Opin Mol Ther. 2010 Aug;12(4):471-7.